Literature DB >> 10722564

Role of toxin functional domains in anthrax pathogenesis.

F Brossier1, M Weber-Levy, M Mock, J C Sirard.   

Abstract

We investigated the role of the functional domains of anthrax toxins during infection. Three proteins produced by Bacillus anthracis, the protective antigen (PA), the lethal factor (LF), and the edema factor (EF), combine in pairs to produce the lethal (PA+LF) and edema (PA+EF) toxins. A genetic strategy was developed to introduce by allelic exchange specific point mutations or in-frame deletions into B. anthracis toxin genes, thereby impairing either LF metalloprotease or EF adenylate cyclase activity or PA functional domains. In vivo effects of toxin mutations were analyzed in an experimental infection of mice. A tight correlation was observed between the properties of anthrax toxins delivered in vivo and their in vitro activities. The synergic effects of the lethal and edema toxins resulted purely from their enzymatic activities, suggesting that in vivo these toxins may act together. The PA-dependent antibody response to LF induced by immunization with live B. anthracis was used to follow the in vivo interaction of LF and PA. We found that the binding of LF to PA in vivo was necessary and sufficient for a strong antibody response against LF, whereas neither LF activity nor binding of lethal toxin complex to the cell surface was required. Mutant PA proteins were cleaved in mice sera. Thus, our data provide evidence that, during anthrax infection, PA may interact with LF before binding to the cell receptor. Immunoprotection studies indicated that the strain producing detoxified LF and EF, isogenic to the current live vaccine Sterne strain, is a safe candidate for use as a vaccine against anthrax.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722564      PMCID: PMC97348          DOI: 10.1128/IAI.68.4.1781-1786.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

1.  Purification of factor I and recognition of a third factor of the anthrax toxin.

Authors:  J L STANLEY; H SMITH
Journal:  J Gen Microbiol       Date:  1961-09

2.  Virulence and immunogenicity in experimental animals of Bacillus anthracis strains harbouring or lacking 110 MDa and 60 MDa plasmids.

Authors:  I Uchida; K Hashimoto; N Terakado
Journal:  J Gen Microbiol       Date:  1986-02

Review 3.  Incompatibility group P plasmids: genetics, evolution, and use in genetic manipulation.

Authors:  C M Thomas; C A Smith
Journal:  Annu Rev Microbiol       Date:  1987       Impact factor: 15.500

4.  Nucleotide sequence of the Streptococcus faecalis plasmid gene encoding the 3'5"-aminoglycoside phosphotransferase type III.

Authors:  P Trieu-Cuot; P Courvalin
Journal:  Gene       Date:  1983-09       Impact factor: 3.688

5.  Cloning and expression of the calmodulin-sensitive Bacillus anthracis adenylate cyclase in Escherichia coli.

Authors:  M Mock; E Labruyère; P Glaser; A Danchin; A Ullmann
Journal:  Gene       Date:  1988-04-29       Impact factor: 3.688

6.  Cloning of the protective antigen gene of Bacillus anthracis.

Authors:  M H Vodkin; S H Leppla
Journal:  Cell       Date:  1983-09       Impact factor: 41.582

7.  Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells.

Authors:  S H Leppla
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

8.  Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process.

Authors:  A M Friedlander
Journal:  J Biol Chem       Date:  1986-06-05       Impact factor: 5.157

9.  Elaboration of Bacillus anthracis antigens in a new, defined culture medium.

Authors:  J D Ristroph; B E Ivins
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

10.  Transposon Tn554: complete nucleotide sequence and isolation of transposition-defective and antibiotic-sensitive mutants.

Authors:  E Murphy; L Huwyler; M do C de Freire Bastos
Journal:  EMBO J       Date:  1985-12-01       Impact factor: 11.598

View more
  49 in total

1.  Clostridium perfringens iota-toxin: mapping of receptor binding and Ia docking domains on Ib.

Authors:  J C Marvaud; T Smith; M L Hale; M R Popoff; L A Smith; B G Stiles
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Progress in rapid screening of Bacillus anthracis lethal factor activity.

Authors:  Michèle Mock; Bernard P Roques
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

3.  Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.

Authors:  Sherry R Crowe; Linda L Ash; Renata J M Engler; Jimmy D Ballard; John B Harley; A Darise Farris; Judith A James
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

4.  Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo.

Authors:  Miroslav S Sarac; Juan R Peinado; Stephen H Leppla; Iris Lindberg
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

5.  A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.

Authors:  G Hermanson; V Whitlow; S Parker; K Tonsky; D Rusalov; M Ferrari; P Lalor; M Komai; R Mere; M Bell; K Brenneman; A Mateczun; T Evans; D Kaslow; D Galloway; P Hobart
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-01       Impact factor: 11.205

6.  Inhibition of the adenylyl cyclase toxin, edema factor, from Bacillus anthracis by a series of 18 mono- and bis-(M)ANT-substituted nucleoside 5'-triphosphates.

Authors:  Hesham Taha; Stefan Dove; Jens Geduhn; Burkhard König; Yuequan Shen; Wei-Jen Tang; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-24       Impact factor: 3.000

7.  Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.

Authors:  Sherry R Crowe; Lori Garman; Renata J M Engler; A Darise Farris; Jimmy D Ballard; John B Harley; Judith A James
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

8.  Bacillus anthracis sortase A (SrtA) anchors LPXTG motif-containing surface proteins to the cell wall envelope.

Authors:  Andrew H Gaspar; Luciano A Marraffini; Elizabeth M Glass; Kristin L Debord; Hung Ton-That; Olaf Schneewind
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

Review 9.  Role of pore-forming toxins in bacterial infectious diseases.

Authors:  Ferdinand C O Los; Tara M Randis; Raffi V Aroian; Adam J Ratner
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

10.  Role of the N-terminal amino acid of Bacillus anthracis lethal factor in lethal toxin cytotoxicity and its effect on the lethal toxin neutralization assay.

Authors:  Anita Verma; Leslie Wagner; Scott Stibitz; Nga Nguyen; Flor Guerengomba; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2008-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.